Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
For patients, we provide the latest patient information leaflets and training materials as well as the technical information for Berlin-Chemie products available in Germany via our Medical Hub.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Within the Menarini Group, Berlin-Chemie is the regional headquarters for the CEE and CIS region and is responsible for more than 30 countries and their local subsidiaries.
As a reliable partner in the healthcare sector, we want to use our products and expertise to help solve the complex challenges in the healthcare sector in these regions. To this end, Berlin-Chemie has established strong partnerships at all levels in many countries. We support doctors and patients with high-quality medical products and technologies to improve the quality of life.
Our regional headquarters
BERLIN-CHEMIE AG
Glienicker Weg 125
12489 Berlin, Deutschland
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO<sup>®</sup> (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Karyopharm and Menarini Receive Full Marketing Authorisation from the European Commission for NEXPOVIO<sup>®</sup> (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
ATGC Co., Ltd. License Agreement Grants RELIFE S.r.l. Exclusive Rights to Register, Promote, Distribute, and Market the Novel Botulinum Toxin Type A (ATGC-100) in Europe and the United Kingdom.
Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH<sup>®</sup> System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early